Meiling Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Meiling Li has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
Haixu Jiang
School of Chinese Materia, Beijing University of Chinese Medicine, Beijing, China
2 shared publicationsHuiqiang Wu
Department of Hematology, The Second Affiliated Hospital of Fujian Medical University
2 shared publicationsYafei Guo
Department of Hematology, The Second Affiliated Hospital of Fujian Medical University
2 shared publicationsZhiyin Cai
Department of Hematology, The Second Affiliated Hospital of Fujian Medical University
2 shared publicationsChangjian Yan
Department of Hematology, The Second Affiliated Hospital of Fujian Medical University
1 shared publicationChaoling Wu
Department of Respiratory Medicine, Affiliated Hospital of JiuJiang University
1 shared publication
Latest Publications
- Open Access
- 5 August 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1880529
Prognostic and biological significance of MRPL13 in multiple myeloma: evidence from multi-cohort, single-cell analyses
Background: Multiple myeloma (MM) is a clonal plasma cell malignancy with high heterogeneity and poor prognosis. Mitochondrial ribosomal protein L13 (MRPL13) has been linked to tumor progression, but its role in MM remains unclear. Methods: We analyzed seven datasets comprising 3,117 patient samples from the Multiple Myeloma Research Foundation (MMRF) CoMMpass study (referred to as the TCGA_MMRF cohort) and the Gene Expression Omnibus (GEO) database to evaluate the association between MRPL13 expression and overall survival (OS). Event-free survival (EFS) analysis was performed in the GSE24080 cohort, and progression-free survival (PFS) analysis was conducted in the GSE136337 cohort. We further analyzed single-cell transcriptomic profiles of 74,986 cells from 24 MM patients to delineate the expression landscape of MRPL13 across distinct cellular populations and functional subclusters and to assess its relationship with the immune microenvironment. We performed functional assays involving siRNA-mediated MRPL13 silencing to investigate its effects on MM cell proliferation and cell-cycle progression in vitro . Results: High MRPL13 expression was associated with adverse clinical features and poor survival and was identified as a potential independent prognostic factor. Single-cell analysis revealed enrichment in metabolically active malignant plasma cells and an immunosuppressive microenvironment. Silencing MRPL13 inhibited proliferation and induced G0/G1 arrest. Conclusion: MRPL13 predicts poor prognosis and promotes MM progression through metabolic and immune regulation, supporting its potential as a prognostic biomarker and therapeutic target.
- 5 August 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1880529
Open AccessPrognostic and biological significance of MRPL13 in multiple myeloma: evidence from multi-cohort, single-cell analyses
Background: Multiple myeloma (MM) is a clonal plasma cell malignancy with high heterogeneity and poor prognosis. Mitochondrial ribosomal protein L13 (MRPL13) has been linked to tumor progression, but its role in MM remains unclear. Methods: We analyzed seven datasets comprising 3,117 patient samples from the Multiple Myeloma Research Foundation (MMRF) CoMMpass study (referred to as the TCGA_MMRF cohort) and the Gene Expression Omnibus (GEO) database to evaluate the association between MRPL13 expression and overall survival (OS). Event-free survival (EFS) analysis was performed in the GSE24080 cohort, and progression-free survival (PFS) analysis was conducted in the GSE136337 cohort. We further analyzed single-cell transcriptomic profiles of 74,986 cells from 24 MM patients to delineate the expression landscape of MRPL13 across distinct cellular populations and functional subclusters and to assess its relationship with the immune microenvironment. We performed functional assays involving siRNA-mediated MRPL13 silencing to investigate its effects on MM cell proliferation and cell-cycle progression in vitro . Results: High MRPL13 expression was associated with adverse clinical features and poor survival and was identified as a potential independent prognostic factor. Single-cell analysis revealed enrichment in metabolically active malignant plasma cells and an immunosuppressive microenvironment. Silencing MRPL13 inhibited proliferation and induced G0/G1 arrest. Conclusion: MRPL13 predicts poor prognosis and promotes MM progression through metabolic and immune regulation, supporting its potential as a prognostic biomarker and therapeutic target.
- Open Access
- 22 June 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1855322
CCDC88C::PDGFRB-rearranged myeloid neoplasm with predominant neutrophilia and rapid response to imatinib: a molecularly defined case report
Myeloid/lymphoid neoplasms with PDGFRB rearrangements are rare hematologic malignancies usually associated with eosinophilia and sensitivity to tyrosine kinase inhibitors, whereas atypical presentations remain poorly defined. We report a 60-year-old man with persistent leukocytosis and thrombocytopenia detected during a routine health examination. Bone marrow examination revealed marked granulocytic proliferation without increased blasts, and peripheral blood showed predominant neutrophilia with only mild eosinophilia. Cytogenetic analysis identified a t(5;14) translocation. RNA sequencing detected an in-frame CCDC88C exon 12::PDGFRB exon 11 fusion, and targeted sequencing additionally identified an ATM frameshift mutation. Treatment with low-dose imatinib (200 mg daily) led to rapid normalization of leukocyte counts within one week and sustained hematologic remission during follow-up. This case broadens the clinicopathologic spectrum of CCDC88C::PDGFRB -rearranged neoplasms and highlights the value of RNA sequencing in identifying actionable kinase fusions in atypical myeloproliferative presentations.
- 22 June 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1855322
Open AccessCCDC88C::PDGFRB-rearranged myeloid neoplasm with predominant neutrophilia and rapid response to imatinib: a molecularly defined case report
Myeloid/lymphoid neoplasms with PDGFRB rearrangements are rare hematologic malignancies usually associated with eosinophilia and sensitivity to tyrosine kinase inhibitors, whereas atypical presentations remain poorly defined. We report a 60-year-old man with persistent leukocytosis and thrombocytopenia detected during a routine health examination. Bone marrow examination revealed marked granulocytic proliferation without increased blasts, and peripheral blood showed predominant neutrophilia with only mild eosinophilia. Cytogenetic analysis identified a t(5;14) translocation. RNA sequencing detected an in-frame CCDC88C exon 12::PDGFRB exon 11 fusion, and targeted sequencing additionally identified an ATM frameshift mutation. Treatment with low-dose imatinib (200 mg daily) led to rapid normalization of leukocyte counts within one week and sustained hematologic remission during follow-up. This case broadens the clinicopathologic spectrum of CCDC88C::PDGFRB -rearranged neoplasms and highlights the value of RNA sequencing in identifying actionable kinase fusions in atypical myeloproliferative presentations.
- Open Access
- 4 June 2026
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 32 (2) , 1-18
Sotagliflozin ameliorates doxorubicin-induced cardiomyopathy by regulating inflammation and mitochondrial dysfunction through the AMPK/mTOR pathway
Sodium‑glucose co‑transport protein inhibitor Sotagliflozin (SOTA) has demonstrated cardiovascular benefits in diabetic patients, while doxorubicin (DOX) is widely used to generate cardiomyopathy experimental models. The present study investigated the cardioprotective mechanisms of SOTA on DOX‑induced heart failure in vitro and in vivo. First, C57BL/6 mice were injected with multiple doses of DOX (total 15 mg/kg), and the in vivo impact of SOTA on cardiac function and cardiomyopathy‑related biochemical signaling was assessed. Next, H9C2 cells were treated with DOX in the presence of SOTA to examine the changes in cell viability, mitochondrial function, inflammation, oxidative stress and cell death‑related signal pathways. SOTA treatment in vivo alleviated cardiac dysfunction and fibrosis while reducing cardiomyocyte apoptosis, inflammation, oxidative stress and mitochondrial dysfunction. In vitro, H9c2 cells exposed to DOX in the presence of SOTA exhibited enhanced cell viability and mitigated apoptosis, inflammation, oxidative stress and mitochondrial damage. Furthermore, cleaved caspase‑3 and inflammatory cytokine (IL‑6, IL‑1β and TNF‑α) levels were decreased. Reactive oxygen species and mitochondrial Ca2+ loading were reduced. Mitochondrial dysfunction was also improved, as indicated by increased JC‑1 aggregates and Bcl‑2/Bax ratios. Notably, SOTA activated 5' AMP‑activated protein kinase (AMPK) and inhibited mTOR signaling while protecting from DOX‑induced cardiomyopathy, suggesting SOTA as a promising therapeutic for heart failure treatment.
- 4 June 2026
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 32 (2) , 1-18
Open AccessSotagliflozin ameliorates doxorubicin-induced cardiomyopathy by regulating inflammation and mitochondrial dysfunction through the AMPK/mTOR pathway
Sodium‑glucose co‑transport protein inhibitor Sotagliflozin (SOTA) has demonstrated cardiovascular benefits in diabetic patients, while doxorubicin (DOX) is widely used to generate cardiomyopathy experimental models. The present study investigated the cardioprotective mechanisms of SOTA on DOX‑induced heart failure in vitro and in vivo. First, C57BL/6 mice were injected with multiple doses of DOX (total 15 mg/kg), and the in vivo impact of SOTA on cardiac function and cardiomyopathy‑related biochemical signaling was assessed. Next, H9C2 cells were treated with DOX in the presence of SOTA to examine the changes in cell viability, mitochondrial function, inflammation, oxidative stress and cell death‑related signal pathways. SOTA treatment in vivo alleviated cardiac dysfunction and fibrosis while reducing cardiomyocyte apoptosis, inflammation, oxidative stress and mitochondrial dysfunction. In vitro, H9c2 cells exposed to DOX in the presence of SOTA exhibited enhanced cell viability and mitigated apoptosis, inflammation, oxidative stress and mitochondrial damage. Furthermore, cleaved caspase‑3 and inflammatory cytokine (IL‑6, IL‑1β and TNF‑α) levels were decreased. Reactive oxygen species and mitochondrial Ca2+ loading were reduced. Mitochondrial dysfunction was also improved, as indicated by increased JC‑1 aggregates and Bcl‑2/Bax ratios. Notably, SOTA activated 5' AMP‑activated protein kinase (AMPK) and inhibited mTOR signaling while protecting from DOX‑induced cardiomyopathy, suggesting SOTA as a promising therapeutic for heart failure treatment.
- Open Access
- 11 September 2025
- Published by Frontiers Media SA in Frontiers in Nutrition
- Vol. 12, 1659000
Association of dietary fiber intake with all-cause and cardiovascular mortality in U.S. adults with metabolic syndrome: NHANES 1999–2018
Background: Low dietary fiber intake is common in the US, despite its health benefits. Individuals with metabolic syndrome (MetS), at high cardiovascular risk, may benefit significantly from higher fiber, but its link to mortality in this group is unclear.Methods: We analyzed prospective data from 10,962 U.S. adults with MetS (NHANES 1999–2018, mean age 58.1). Baseline fiber intake (g/day) was assessed via 24-h recalls. MetS was defined by ATP III criteria. Mortality (all-cause, CVD-specific) was tracked via the National Death Index (median follow-up 102 months). Cox models estimated hazard ratios (HRs) for mortality associated with fiber intake, adjusted for demographics, socioeconomic status, lifestyle, and comorbidities.Results: Over follow-up, 2,617 deaths occurred (887 CVD-specific). Higher fiber intake was associated with significantly lower mortality. Our analysis suggested a potential threshold effect near 21.7 g/day of fiber intake. Below this, each additional 5 g fiber reduced all-cause mortality risk by 7% (HR = 0.93, 95% CI: 0.91–0.96, p < 0.0001). Comparing highest to lowest tertile intake, adjusted HRs were 0.80 (95% CI 0.72–0.89, p < 0.0001) for all-cause and 0.61 (0.51–0.73, p < 0.0001) for CVD mortality. Results were robust in sensitivity analyses.Conclusion: In U.S. adults with MetS, higher dietary fiber intake was associated with significantly lower all-cause and CVD mortality. Benefits were most pronounced at lower intakes, plateauing around 22 g/day, suggesting achieving moderate fiber intake near recommendations offers substantial survival benefits in this high-risk group.
- 11 September 2025
- Published by Frontiers Media SA in Frontiers in Nutrition
- Vol. 12, 1659000
Open AccessAssociation of dietary fiber intake with all-cause and cardiovascular mortality in U.S. adults with metabolic syndrome: NHANES 1999–2018
Background: Low dietary fiber intake is common in the US, despite its health benefits. Individuals with metabolic syndrome (MetS), at high cardiovascular risk, may benefit significantly from higher fiber, but its link to mortality in this group is unclear.Methods: We analyzed prospective data from 10,962 U.S. adults with MetS (NHANES 1999–2018, mean age 58.1). Baseline fiber intake (g/day) was assessed via 24-h recalls. MetS was defined by ATP III criteria. Mortality (all-cause, CVD-specific) was tracked via the National Death Index (median follow-up 102 months). Cox models estimated hazard ratios (HRs) for mortality associated with fiber intake, adjusted for demographics, socioeconomic status, lifestyle, and comorbidities.Results: Over follow-up, 2,617 deaths occurred (887 CVD-specific). Higher fiber intake was associated with significantly lower mortality. Our analysis suggested a potential threshold effect near 21.7 g/day of fiber intake. Below this, each additional 5 g fiber reduced all-cause mortality risk by 7% (HR = 0.93, 95% CI: 0.91–0.96, p < 0.0001). Comparing highest to lowest tertile intake, adjusted HRs were 0.80 (95% CI 0.72–0.89, p < 0.0001) for all-cause and 0.61 (0.51–0.73, p < 0.0001) for CVD mortality. Results were robust in sensitivity analyses.Conclusion: In U.S. adults with MetS, higher dietary fiber intake was associated with significantly lower all-cause and CVD mortality. Benefits were most pronounced at lower intakes, plateauing around 22 g/day, suggesting achieving moderate fiber intake near recommendations offers substantial survival benefits in this high-risk group.
- Open Access
- 16 July 2025
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 12, 1580989
The effects on clinical characteristics, potential factors and outcomes in SAPHO patients during the COVID-19 epidemic
Objectives: The coronavirus disease (COVID-19) pandemic has potentially impacted the care of patients with rheumatic diseases, including Synovitis, Acne, Pustulosis, Hyperostosis, and Osteitis (SAPHO) syndrome. We investigates the effects on clinical characteristics, potential factors, and outcomes in SAPHO patients during the COVID-19 pandemic.Methods: SAPHO patients were recruited for this cross-sectional study from Fangshan Hospital of Beijing University of Chinese Medicine. In total, 375 patients (mean age, 47.5 years, 72.53% females) were asked about demographic data, disease status, current treatments, and clinical manifestations during the epidemic, and potential relationships were analyzed.Results: Among 375 included patients, 329 were infected with coronavirus 2019. Compared with non-infected patients, infected ones were more likely to have higher disease activity (p = 0.006). However, Janus kinase (JAK) inhibitor use was lower in detected COVID-19 cases than in non-infected cases in our cohort. Disease symptoms during COVID-19 were more commonly present in the non-JAK group than JAK groups, including rhinorrhea (p = 0.030), nasal congestion (p = 0.023), sore throat (p = 0.042), pneumonia (p = 0.044), headache (p = 0.023), and prevalence of palpitation (p = 0.015). In this study, 29 participants underwent tonsillectomy. Tonsillectomized patients showed a significantly higher prevalence of pneumonia than patients who did not undergo tonsillectomy (p = 0.009). The associated effect factors were displayed in the case of previous tonsillectomy using multivariate analysis and Firth’s penalized likelihood. JAK inhibitor use (p = 0.025) and pneumonia (p = 0.011) were more likely to develop in patients with a history of tonsillectomy.Conclusion: Disease activity was inversely correlated with JAK inhibitor use in SAPHO patients with COVID-19 during the pandemic. Thus, JAK antagonists have protective effects on SAPHO patients with infections and can significantly mitigate new clinical crown symptoms. However, there was a significant negative correlation between tonsillectomy and the prevalence of SAPHO with COVID-19, which demonstrates that tonsillectomy may be associated with an increased risk of COVID-19 adverse outcomes, especially in cases of taste disorders and pneumonia.
- 16 July 2025
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 12, 1580989
Open AccessThe effects on clinical characteristics, potential factors and outcomes in SAPHO patients during the COVID-19 epidemic
Objectives: The coronavirus disease (COVID-19) pandemic has potentially impacted the care of patients with rheumatic diseases, including Synovitis, Acne, Pustulosis, Hyperostosis, and Osteitis (SAPHO) syndrome. We investigates the effects on clinical characteristics, potential factors, and outcomes in SAPHO patients during the COVID-19 pandemic.Methods: SAPHO patients were recruited for this cross-sectional study from Fangshan Hospital of Beijing University of Chinese Medicine. In total, 375 patients (mean age, 47.5 years, 72.53% females) were asked about demographic data, disease status, current treatments, and clinical manifestations during the epidemic, and potential relationships were analyzed.Results: Among 375 included patients, 329 were infected with coronavirus 2019. Compared with non-infected patients, infected ones were more likely to have higher disease activity (p = 0.006). However, Janus kinase (JAK) inhibitor use was lower in detected COVID-19 cases than in non-infected cases in our cohort. Disease symptoms during COVID-19 were more commonly present in the non-JAK group than JAK groups, including rhinorrhea (p = 0.030), nasal congestion (p = 0.023), sore throat (p = 0.042), pneumonia (p = 0.044), headache (p = 0.023), and prevalence of palpitation (p = 0.015). In this study, 29 participants underwent tonsillectomy. Tonsillectomized patients showed a significantly higher prevalence of pneumonia than patients who did not undergo tonsillectomy (p = 0.009). The associated effect factors were displayed in the case of previous tonsillectomy using multivariate analysis and Firth’s penalized likelihood. JAK inhibitor use (p = 0.025) and pneumonia (p = 0.011) were more likely to develop in patients with a history of tonsillectomy.Conclusion: Disease activity was inversely correlated with JAK inhibitor use in SAPHO patients with COVID-19 during the pandemic. Thus, JAK antagonists have protective effects on SAPHO patients with infections and can significantly mitigate new clinical crown symptoms. However, there was a significant negative correlation between tonsillectomy and the prevalence of SAPHO with COVID-19, which demonstrates that tonsillectomy may be associated with an increased risk of COVID-19 adverse outcomes, especially in cases of taste disorders and pneumonia.
- Open Access
- 23 June 2023
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 14, 1204652
Platelets-related signature based diagnostic model in rheumatoid arthritis using WGCNA and machine learning
Background and aim: Rheumatoid arthritis (RA) is an autoinflammatory disease that may lead to severe disability. The diagnosis of RA is limited due to the need for biomarkers with both reliability and efficiency. Platelets are deeply involved in the pathogenesis of RA. Our study aims to identify the underlying mechanism and screening for related biomarkers.Methods: We obtained two microarray datasets (GSE93272 and GSE17755) from the GEO database. We performed Weighted correlation network analysis (WGCNA) to analyze the expression modules in differentially expressed genes identified from GSE93272. We used KEGG, GO and GSEA enrichment analysis to elucidate the platelets-relating signatures (PRS). We then used the LASSO algorithm to develop a diagnostic model. We then used GSE17755 as a validation cohort to assess the diagnostic performance by operating Receiver Operating Curve (ROC).Results: The application of WGCNA resulted in the identification of 11 distinct co-expression modules. Notably, Module 2 exhibited a prominent association with platelets among the differentially expressed genes (DEGs) analyzed. Furthermore, a predictive model consisting of six genes (MAPK3, ACTB, ACTG1, VAV2, PTPN6, and ACTN1) was constructed using LASSO coefficients. The resultant PRS model demonstrated excellent diagnostic accuracy in both cohorts, as evidenced by area under the curve (AUC) values of 0.801 and 0.979.Conclusion: We elucidated the PRSs occurred in the pathogenesis of RA and developed a diagnostic model with excellent diagnostic potential.
- 23 June 2023
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 14, 1204652
Open AccessPlatelets-related signature based diagnostic model in rheumatoid arthritis using WGCNA and machine learning
Background and aim: Rheumatoid arthritis (RA) is an autoinflammatory disease that may lead to severe disability. The diagnosis of RA is limited due to the need for biomarkers with both reliability and efficiency. Platelets are deeply involved in the pathogenesis of RA. Our study aims to identify the underlying mechanism and screening for related biomarkers.Methods: We obtained two microarray datasets (GSE93272 and GSE17755) from the GEO database. We performed Weighted correlation network analysis (WGCNA) to analyze the expression modules in differentially expressed genes identified from GSE93272. We used KEGG, GO and GSEA enrichment analysis to elucidate the platelets-relating signatures (PRS). We then used the LASSO algorithm to develop a diagnostic model. We then used GSE17755 as a validation cohort to assess the diagnostic performance by operating Receiver Operating Curve (ROC).Results: The application of WGCNA resulted in the identification of 11 distinct co-expression modules. Notably, Module 2 exhibited a prominent association with platelets among the differentially expressed genes (DEGs) analyzed. Furthermore, a predictive model consisting of six genes (MAPK3, ACTB, ACTG1, VAV2, PTPN6, and ACTN1) was constructed using LASSO coefficients. The resultant PRS model demonstrated excellent diagnostic accuracy in both cohorts, as evidenced by area under the curve (AUC) values of 0.801 and 0.979.Conclusion: We elucidated the PRSs occurred in the pathogenesis of RA and developed a diagnostic model with excellent diagnostic potential.
- 20 July 2020
- Published by Springer Nature in Chinese Journal of Integrative Medicine
- Vol. 28 (1) , 81-87
Shenqi Fuzheng Injection (参芪扶正注射液) Combined with Chemotherapy for Acute Leukemia: A Meta-Analysis
Abstract Objective To evaluate to the efficacy and safety of Shenqi Fuzheng Injection (参芪扶正注射液, SFI) combined with chemotherapy in the treatment of acute leukemia (AL) by meta-analysis. Methods PubMed, Cochrane library, Embase, SinoMed, China National Knowledge Infrastructure (CNKI), VIP Journal Integration Platform, Wanfang Database were searched from establishment to November 1, 2018. The randomized controlled trials (RCTs) of SFI combined with chemotherapy in the treatment of AL were included. The Cochrane risk assessment form (RevMan 5.1) was used to evaluate the quality of included studies. Results A total of 14 RCTs and 1,088 patients was included. The quality evaluation were mostly low risk or unclear. Meta-analysis showed that compared with chemotherapy alone, SFI combined with chemotherapy can improve the total clinical effective rate in patients with AL (RR=1.15, 95% CI: 1.056–1.177; P=0.0001), and relieve adverse reactions caused by chemotherapy drugs, including infection (RR=0.561, 95% CI: 0.397–0.792; P=0.001), nausea and vomiting (RR=0.662, 95% CI: 0.524–0.835; P=0.001), bleeding (RR=0.548, 95% CI: 0.39–0.768; P=0.0001), cardiotoxicity (RR=0.230, 95% CI: 0.080–0.660; P=0.006) and hyperhidrosis (RR=0.348, 95% CI: 0.208–0.581; P=0.0001). The incidence rates of adverse reactions in SFI combined with chemotherapy group were significantly lower than that of the chemotherapy alone group (P Conclusions Shenqi Fuzheng Injection combined with chemotherapy has good efficacy and safety for AL, and it can alleviate the adverse reactions caused by chemotherapy. However, subject to the limitations of the methodological quality of the literature, the conclusions of this study need to be further verified by large-scale and multi-center RCTs.
- 20 July 2020
- Published by Springer Nature in Chinese Journal of Integrative Medicine
- Vol. 28 (1) , 81-87
Shenqi Fuzheng Injection (参芪扶正注射液) Combined with Chemotherapy for Acute Leukemia: A Meta-Analysis
Abstract Objective To evaluate to the efficacy and safety of Shenqi Fuzheng Injection (参芪扶正注射液, SFI) combined with chemotherapy in the treatment of acute leukemia (AL) by meta-analysis. Methods PubMed, Cochrane library, Embase, SinoMed, China National Knowledge Infrastructure (CNKI), VIP Journal Integration Platform, Wanfang Database were searched from establishment to November 1, 2018. The randomized controlled trials (RCTs) of SFI combined with chemotherapy in the treatment of AL were included. The Cochrane risk assessment form (RevMan 5.1) was used to evaluate the quality of included studies. Results A total of 14 RCTs and 1,088 patients was included. The quality evaluation were mostly low risk or unclear. Meta-analysis showed that compared with chemotherapy alone, SFI combined with chemotherapy can improve the total clinical effective rate in patients with AL (RR=1.15, 95% CI: 1.056–1.177; P=0.0001), and relieve adverse reactions caused by chemotherapy drugs, including infection (RR=0.561, 95% CI: 0.397–0.792; P=0.001), nausea and vomiting (RR=0.662, 95% CI: 0.524–0.835; P=0.001), bleeding (RR=0.548, 95% CI: 0.39–0.768; P=0.0001), cardiotoxicity (RR=0.230, 95% CI: 0.080–0.660; P=0.006) and hyperhidrosis (RR=0.348, 95% CI: 0.208–0.581; P=0.0001). The incidence rates of adverse reactions in SFI combined with chemotherapy group were significantly lower than that of the chemotherapy alone group (P Conclusions Shenqi Fuzheng Injection combined with chemotherapy has good efficacy and safety for AL, and it can alleviate the adverse reactions caused by chemotherapy. However, subject to the limitations of the methodological quality of the literature, the conclusions of this study need to be further verified by large-scale and multi-center RCTs.